Crystagen CRY
Bioregulator peptide
Bioregulator tripeptide Glu-Asp-Pro from the Khavinson programme, described as an immune-system regulator and reported as a Thymalin component.
Evidence level. Little or no public data, or the exact identity is still being confirmed. About the badges
- Class
- Bioregulator peptide
- Category
- Bioregulator Peptides
- Type
- Single compound
- Abbreviation
- CRY
- Development and regulatory status
- Not approved by FDA or EMA, research-only bioregulator peptide
What researchers study
Tripeptide Glu-Asp-Pro (EDP) from the Khavinson programme, described as an immune-system regulator and reported as a component of the Thymalin extract. Little peer-reviewed data exist, mostly from one research network.
Research areas
- Thymus and spleen explant growth in rats
- Macrophage lymphocyte-activating factor production
- B-cell and spleen ageing models
- Thymic epithelial cell proliferation
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- rodent tissue culture, patent data
A developer patent reports that the peptide increased thymus explant growth area by about 24% at day 3 in 24-month-old rat tissue
- animal tissue study
In a Russian-language study of ageing spleen, the peptide activated the B-cell arm of immunity without driving cell renewal
- patent data
The patent also describes 38 treated and 32 control elderly patients with immune-marker changes, but design details are limited and no independent confirmation was found
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- ThymalinEDP is reported as a component of the Thymalin extract
- VilonStudied alongside Crystagen in ageing-spleen immune peptide work
- Thymosin Alpha-1Separate thymic peptide with overlapping immune-regulation research focus
